Cargando…

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

Detalles Bibliográficos
Autores principales:	Colomer, R, Monzo, M, Tusquets, I, Rifa, J, Baena, JM, Barnadas, A, Calvo, L, Carabantes, F, Crespo, C, Muñoz, M, Llombart, A, Plazaola, A, Alba, E, Fuster, D, Gilabert, M, Lloveras, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231913/ http://dx.doi.org/10.1186/bcr1233

Ejemplares similares

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
por: Garcia-Casado, Zaida, et al.
Publicado: (2010)

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
por: Wang, Shunde, et al.
Publicado: (2018)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
por: Balakrishnan, A, et al.
Publicado: (2011)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
por: Hoeflich, Klaus P., et al.
Publicado: (2016)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
por: Rezaei, Ako, et al.
Publicado: (2022)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)

Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue
por: Alabiad, Mohamed Ali, et al.
Publicado: (2022)

Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
por: Edris, Alaa, et al.
Publicado: (2023)

Genetic variants of CYP19 (aromatase) and breast cancer risk
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
por: De Luca, Michele, et al.
Publicado: (2022)

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
por: Miller, William R, et al.
Publicado: (2010)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
por: Dempsey, Jacqueline M., et al.
Publicado: (2018)

Pyridine based dual binding site aromatase (CYP19A1) inhibitors
por: Eissa, Ahmed G., et al.
Publicado: (2023)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats
por: Kamal, Datu Agasi Mohd, et al.
Publicado: (2022)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Association Study of Aromatase Gene (CYP19A1) in Essential Hypertension
por: Shimodaira, Masanori, et al.
Publicado: (2008)

The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization
por: Lee, Kyung-Hee, et al.
Publicado: (2014)

Morphological and Functional Changes in Skin of Adult Male Rats Chronically Treated with Letrozole, a Nonsteroidal Inhibitor of Cytochrome P450 Aromatase
por: Misiakiewicz-Has, Kamila, et al.
Publicado: (2020)

Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats
por: Shaaban, Zahra, et al.
Publicado: (2022)

The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?
por: Glubb, Dylan M., et al.
Publicado: (2017)

Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
por: Siegelmann-Danieli, N, et al.
Publicado: (1999)

Cyp19a1 (Aromatase) Expression in the Xenopus Brain at Different Developmental Stages
por: Coumailleau, P, et al.
Publicado: (2014)

Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
por: Daldorff, Stine, et al.
Publicado: (2017)

Aromatase Deficiency due to a Novel Mutation in CYP19A1 Gene
por: Unal, Edip, et al.
Publicado: (2018)

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells
por: Abrhale, Tesfom, et al.
Publicado: (2011)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in Postmenopausal Women
por: Lin, Jennifer H., et al.
Publicado: (2012)

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment
por: Sortica, Vinicius A, et al.
Publicado: (2016)

The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
por: Lisztwan, Joanna, et al.
Publicado: (2008)

A case of Aromatase deficiency due to a novel CYP19A1 mutation
por: Gagliardi, Lucia, et al.
Publicado: (2014)

Evaluation of coding-independent functions of the transcribed bovine aromatase pseudogene CYP19P1
por: Chwalisz, Marina, et al.
Publicado: (2014)

Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer
por: Zins, Karin, et al.
Publicado: (2014)

A Novel Homozygous CYP19A1 Gene Mutation Causing Aromatase Deficiency
por: Hathi, Deep, et al.
Publicado: (2022)

Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth
por: Ma, Wen‐Lung, et al.
Publicado: (2022)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s6il9v5j2fobbnbspksphpqtdf